Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor α negative fulvestrant-resistant MCF-7 cells

International Journal of Oncology

Volumn 29, Issue 5, 2006, Pages 1237-1246

  Liu, Hong ^a   Cheng, Dong ^a   Weichel, Alyssa K ^a   Osipo, Clodia ^a   Wing, Laura K ^a   Chen, Bin ^a   Louis, Teresa E ^a   Jordan, V Craig ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Breast cancer; Breast cancer resistant protein; Chemosensitivity; EGFR; Fulvestrant resistance

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; DEMETHOXYFUMITREMORGIN C; DRUG DERIVATIVE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOXANTRONE; PIPERAZINE DERIVATIVE; PROTEIN KINASE B; QUINAZOLINE DERIVATIVE; TUMOR PROTEIN;

ARTICLE; BREAST TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOXANTRONE; NEOPLASM PROTEINS; PHOSPHORYLATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES;

EID: 39049175084     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.5.1237     Document Type: Article

References (52)

1. Jensen EV and Jordan VC: The estrogen receptor: a model for molecular medicine. The Dorothy P. London AACR Prize for Translational Research. Clin Cancer Res 9: 1980-1989, 2003.
2. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717, 2005.
3. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A and Morris C: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396-3403, 2002.
4. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R and Buzdar A: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386-3395, 2002.
5. Dauvois S, Danielian PS, White R and Parker MG: Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 89: 4037-4041, 1992.
6. Gibson M, Nemmers L, Beckman W Jr, Davis V, Curtis S and Korach K: The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129: 2000-2010, 1991.
7. Wakeling AE, Dukes M and Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873, 1991.
8. Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman J, Frandsen T, Spang-Thomsen M, Fuqua SA and Clarke R: MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the non-steroidal antiestrogen tamoxifen. Cancer Res 57: 3486-3493, 1997. (Pubitemid 27355496)
9. Lykkesfeldt AE, Larsen SS and Briand P: Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 61: 529-534, 1995.
10. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM and Nicholson RI: Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142: 2776-2788, 2001. (Pubitemid 32575512)
11. Sommer A, Hoffmann J, Lichtner RB, Schneider MR and Parczyk K: Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol 85: 33-47, 2003. (Pubitemid 36694275)
12. Rabindran SK, Ross DD, Doyle LA, Yang W and Greenberger LM: Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60: 47-50, 2000. (Pubitemid 30058728)
13. Pink JJ and Jordan VC: Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56: 2321-2330, 1996. (Pubitemid 26154081)
14. Catherino WH and Jordan VC: Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue. Cancer Lett 92: 39-47, 1995.
15. Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L and Jordan VC: Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95: 1586-1597, 2003. (Pubitemid 37455926)
16. Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B and Jordan VC: Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells. Gynecol Oncol 85: 498-506, 2002.
17. Sainsbury JR, Farndon JR, Sherbet GV and Harris AL: Epidermal-growth- factor receptors and oestrogen receptors in human breast cancer. Lancet i: 364-366, 1985.
18. Davidson NE, Gelmann EP, Lippman ME and Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216-223, 1987.
19. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE and Nicholson RI: Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-1044, 2003.
20. De Cremoux P, Tran-Perennou C, Brockdorff B, Boudou E, Brunner N, Magdelenat H and Lykkesfeldt A: Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Relat Cancer 10: 409-418, 2003.
21. Arteaga CL: Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7: 31-39, 2002.
22. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
23. Gottesman MM, Fojo T and Bates SE: Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58, 2002.
24. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H and Kohno S: Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65: 1541-1546, 2005.
25. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y and Sugimoto Y: Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3: 1119-1125, 2004.
26. Elkind NB, Szentpetery Z, Apati A, Ozvegy-Laczka C, Varady G, Ujhelly O, Szabo K, Homolya L, Varadi A, Buday L, Keri G, Nemet K and Sarkadi B: Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res 65: 1770-1777, 2005.
27. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE and Nicholson RI: The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144: 5105-5117, 2003.
28. Kurebayashi J, Okubo S, Yamamoto Y and Sonoo H: Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer 11: 38-41, 2004.
29. Wakeling AE, Nicholson RI and Gee JM: Prospects for combining hormonal and non-hormonal growth factor inhibition. Clin Cancer Res 7: S4350-S4355, 2001.
30. Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Vigano L, Fumagalli M, Menard S and Gianni L: Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level. J Cell Physiol 198: 259-268, 2004.
31. Allen JD and Schinkel AH: Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1: 427-434, 2002.
32. Ejendal KF and Hrycyna CA: Multidrug resistance and cancer: the role of the human ABC transporter ABCG2. Curr Protein Pept Sci 3: 503-511, 2002.
33. Han B and Zhang JT: Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents 4: 31-42, 2004.
34. Doyle LA and Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358, 2003.
35. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD and Beck WT: Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. Cancer Res 64: 1247-1251, 2004.
36. Imai Y, Ishikawa E, Asada S and Sugimoto Y: Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 65: 596-604, 2005.
37. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T and Greenberger LM: Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 58: 5850-5858, 1998.
38. Ferrer A, Marce S, Bellosillo B, Villamor N, Bosch F, Lopez-Guillermo A, Espinet B, Sole F, Montserrat E, Campo E and Colomer D: Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. Oncogene 23: 8941-8949, 2004.
39. Bhalla K, Ibrado A, Tourkina E, Tang C, Grant S, Bullock G, Huang Y, Ponnathpur V and Mahoney M: High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 82: 3133-3140, 1993. (Pubitemid 23334941)
40. Huisman MT, Chhatta AA, van Tellingen O, Beijnen JH and Schinkel AH: MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer, 2005.
41. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R and Slamon DJ: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96: 739-749, 2004.
42. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J and Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
43. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte P, Green M, Ward C, Mayne K and Extra J-M: Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 Study Group. J Clin Oncol: JCO.2005.2004.2173, 2005.
44. Sirotnak FM, Zakowski MF, Miller VA, Scher HI and Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892, 2000.
45. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A and Johnson DH: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22: 777-784, 2004. (Pubitemid 41103588)
46. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A and Johnson DH: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22: 785-794, 2004. (Pubitemid 41103589)
47. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ III, Gilbertson R, Germain GS, Harwood FC and Houghton PJ: Gefitinib enhances the antitumor activity and oral bioavailability of Irinotecan in mice. Cancer Res 64: 7491-7499, 2004.
48. Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang X-Y, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC and Kaufmann SH: The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res 61: 739-748, 2001.
49. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E and Traxler P: Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64: 2333-2337, 2004.
50. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K and Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multi-drug transporter. Mol Pharmacol 65: 1485-1495, 2004. (Pubitemid 38668306)
51. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ and Gibson KH: ZD1839 (Iressa): an orally active ihibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62: 5749-5754, 2002.
52. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Muller S, Klebl B, Cotten M, Keri G, Wissing J and Daub H: Cellular targets of Gefitinib. Cancer Res 65: 379-382, 2005.